Breaking News, Collaborations & Alliances

Rentschler Biopharma Enters COVID-19 Vax Agreement with BioNTech

Will serve as CDMO partner for drug substance manufacturing of BNT162b2.

By: Contract Pharma

Contract Pharma Staff

Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has entered an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.   Rentschler Biopharma will be responsible for...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters